Genkyotex (Euronext Paris and Brussels: GKTX) is the leading biopharmaceutical company developing NOX therapies. Its unique therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple disease processes, such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration.
Genkyotex’s platform enables the identification of orally available small-molecules that selectiv...
Genkyotex (Euronext Paris and Brussels: GKTX) is the leading biopharmaceutical company developing NOX therapies. Its unique therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple disease processes, such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration.
Genkyotex’s platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes. From this, Genkyotex is developing a pipeline of first-in-class product candidates targeting one or multiple NOX enzymes.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.